Clinical guidance for the use of dupilumab in eosinophilic esophagitis: A yardstick

Seema S. Aceves, Evan S. Dellon, Matthew Greenhawt, Ikuo Hirano, Chris A. Liacouras, Jonathan M. Spergel*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

The Joint Task Force for the American Academy of Allergy Asthma Immunology and American College of Allergy Asthma Immunology and the American Gastroenterology Association recently published guidelines for the management of eosinophilic esophagitis (EoE). Because the guideline was published, dupilumab became the first and only medication to gain regulatory approval for the treatment of EoE. This expert opinion document provides a framework for how the clinician can consider using dupilumab in the treatment strategy for patients with EoE.

Original languageEnglish (US)
Pages (from-to)371-378
Number of pages8
JournalAnnals of Allergy, Asthma and Immunology
Volume130
Issue number3
DOIs
StatePublished - Mar 2023

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Clinical guidance for the use of dupilumab in eosinophilic esophagitis: A yardstick'. Together they form a unique fingerprint.

Cite this